Inocras and Summit Pharma International Corp collaborate to transform clinical genomics in Japan

US-based Inocras Inc. and Summit Pharmaceuticals International Corporation have signed a Memorandum of understanding (MoU) to jointly explore the commercialisation of their whole genome sequencing (WGS) analysis services. This collaboration aims to revolutionise healthcare in Japan by leveraging genomic data and bioinformatics to better understand and treat cancer and other genetic conditions.

Inocras, a leader in whole-genome sequencing (WGS) and bioinformatics, has partnered with SPI to bring cutting-edge genomic solutions to the Japanese market. In particular, their proprietary technology and bioinformatics pipeline are expected to provide valuable insights in genomic medicine.

Inocras and SPI will develop a business plan to integrate WGS into Japan's healthcare system. This effort includes assessing market potential, developing operational models, and evaluating clinical impact. Input from key opinion leaders and other stakeholders will help shape future developments. Future plans include establishing a WGS lab and enhancing local bioinformatics capabilities.

WGS reads an individual’s entire genome, generating vast data. Inocras' bioinformatics platform transforms this data into actionable clinical insights, enabling precise diagnoses support and personalised treatments.